Physician profile
David R Bierer
NPI 1447273024
$1,015.59
in general payments reported to CMS, 2019-2025
22 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $167 · 2022: $31.61 · 2023: $158 · 2024: $199 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493 · Long Term Medical Supply Or Device Loan: $32.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.58 |
| Long Term Medical Supply Or Device Loan | $32.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $101.56 | 2019-2025 | |
| Coopersurgical, INC. | $94.44 | 2019-2025 | Paragard T 380a |
| Exeltis, USA INC. | $90.98 | 2023-2025 | Slynd |
| Astellas Pharma US INC | $85.50 | 2023-2025 | Veozah |
| Duchesnay USA Incorporated | $81.34 | 2019-2020 | |
| Hologic Sales and Service, LLC | $72.47 | 2019-2025 | Novasure |
| Abbvie INC. | $72.06 | 2020-2024 | Lo Loestrin Fe, Liletta |
| Baxter Healthcare | $59.20 | 2024-2025 | Hillrom - Spot Vision Screener, Perclot |
| Allergan, INC. | $53.83 | 2019-2020 | |
| Biogen, INC. | $47.65 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $34.72 | 2019-2020 | |
| Shield Therapeutics INC | $27.51 | 2023-2024 | Accrufer |
| Ethicon US, LLC | $26.87 | 2019 | |
| Sumitomo Pharma America, INC. | $25.51 | 2025 | Myfembree |
| Boston Scientific Corporation | $24.37 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.92 | 2023-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $21.86 | 2023-2025 | |
| Evofem Biosciences, INC. | $16.83 | 2023 | Phexxi |
| Roche Diagnostics Corporation | $16.41 | 2019 | |
| Becton, Dickinson and Company | $16.40 | 2024 | Bd Onclarity |
| Lupin INC. | $11.20 | 2020 | |
| Amag Pharmaceuticals, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bierer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.